KKR Real Estate Finance Trust Inc. Q3 FY2026 earnings call

• Strategic Review: A committee of independent directors is evaluating strategic alternatives with the help of financial and legal advisors; no further commentary provided due to ongoing nature.
• Portfolio Repayments: Strong repayment activity totaling $2.4 billion year-to-date, exceeding the $2 billion annual expectation. Q3 repayments reached $1.2 billion, matching full-year totals from 2024 and 2025. Over 80% of repayments came from older vintages (2021-2022), accelerating portfolio rotation.
• Watch List & Legacy Exposure: Resolved three additional watch list loans during the quarter. Resolution timelines for remaining assets are extending into H1 2027 due to challenging liquidity and valuation environments.
• Origination Activity: Originated $157 million in new loans, including Class A senior housing and Texas office properties. Pace remains measured to maintain balance sheet flexibility.
• Balance Sheet Strength: Liquidity increased to approximately $853 million (including cash, held principal, and undrawn revolver capacity), one of the highest levels in history. Leverage declined significantly, with debt-to-equity dropping from 2.6x to 2.2x and total leverage from 4.3x to 3.1x.
• Financing Optimization: Completed the retirement of two CRE CLOs via optional redemptions, optimizing the financing structure as collateral pools shrank.

The company reported a GAAP net loss of $6 million, or negative 11 cents per share. Distributable earnings were impacted significantly by realized losses and strategic review expenses, resulting in a distributable loss of $152 million, or negative $2.64 per share. However, distributable earnings before realized losses and strategic review expenses were positive at $5 million, or 9 cents per share. The company paid a cash dividend of 10 cents per share for the third quarter.

• Reserves: Management indicated that an increase in reserves could occur in the near term as resolution processes advance and market conditions evolve under higher interest rates.
• Resolution Timelines: Previously anticipated transactions are likely to extend into the first half of 2027 due to challenging market dynamics.
• Leverage: Expect leverage to remain below historical target ranges in the fourth quarter.
• Originations: Pace of originations expected to remain measured, focusing on balance sheet flexibility rather than dollar-for-dollar replacement of repayments.
• Strategic Expenses: Strategic review costs are ongoing and back-ended, with expectations for higher expenses in Q4 compared to Q3.

• Interest Rate Pressure: Rising interest rates are increasing debt service costs for borrowers and reducing refinancing proceeds, particularly for assets financed at peak valuations in 2021-2022.
• Credit Losses: Extended resolution timelines and lower asset values may result in additional credit losses, especially in multifamily sectors.
• Valuation Opaqueness: Difficulty in pricing certain assets due to slow transaction markets and lack of comparable comps may delay accurate marking of worst-case scenarios.
• Refinancing Risk: Loans with lower debt yields (e.g., 5.5%-6%) face acute refinancing challenges, potentially leading to borrower capitulation and loss absorption.

Q: Analyst asked why management has not taken 'worst-case' marks/reserves earlier given potential opacity in market comps. / A: CEO explained that current watch list resolutions involve some market opaqueness and slower transaction velocities, making it difficult to establish precise baselines immediately. He noted that multifamily vintages from 2021-2022 are most impacted by rate hikes, with average debt yields in the sixes but significant risk at the lower end. Management is closely monitoring these loans as they approach maturity, observing real velocity in repayments but also increased borrower sensitivity to value resets.

Q: Analyst requested details on the Boston Life Science loan resolution and commented on multifamily debt yields and LTV risks. / A: COO clarified that the Boston Life Science loan was non-recourse; as values dropped, the loan was assigned back to the primary lender, resulting in a loss on KREF’s portion which is now removed from the portfolio. Regarding multifamily, CEO stated that 5.5%-6% debt yields require careful analysis of embedded growth (e.g., NYC/SF vs. Sunbelt) and sponsor liquidity/capitulation. He noted slight increases in borrower capitulation in multifamily compared to prior periods, indicating tighter refinancing conditions.

Q: Analyst questioned if KREF would adopt an alternative strategy to fund REO with leverage for multifamily, similar to other strategies, given potential market trough. / A: CEO emphasized that every issue is evaluated individually to maximize recovery, citing successful stabilization in Raleigh and life science cases where tenant gaps created net costs. He did not foresee a large wave of multifamily REO opportunities requiring such a strategy, suggesting isolated situations might need reserves but not a systemic shift to holding leveraged REO portfolios.

Q: Analyst asked about active participation in the market despite low leverage/high liquidity, and how the strategic review impacts employee motivation and buybacks. / A: CEO confirmed KREF is an active participant, having originated loans this quarter, and noted the team invests for multiple KKR capital pools ($43B AUM). He explained that the slowdown in buybacks and cautious origination pace were driven by the desire to reduce leverage ahead of uncertainty, heavy back-end repayments in Q3, and the strategic review process which naturally pauses capital allocation decisions like buybacks until the review concludes.